NCT06103487
Long Term Follow-Up for RGX-111
Enrolling by Invitation
Not specifiedAll AgesObservationalREGENXBIO Inc.
~21 participants
Updated 2026-04-29 on ClinicalTrials.gov
What's tested:No Intervention
At a glance
Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Evaluation of the long-term safety of RGX-111
Measured over 5 years inclusive of parent study
Conditions
Where it's being run
2 sites across 2 statesCalifornia1
Rio Grande do Sul1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
To be eligible, a participant must have previously received RGX-111 in a separate parent trial.
Participant or participant's legal guardian(s) is/(are) willing and able to provide written, signed informed consent.
Exclusion
None.
What this trial measures
- Evaluation of the long-term safety of RGX-1115 years inclusive of parent study
Incidences of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) over time using CTCAE Version 5.0